EGRX - Eagle Pharmaceuticals Inc-DE Stock Price, Fair Value and News

5.72USD-0.02 (-0.35%)Market Closed

Market Summary

USD5.72-0.02

Market Closed

-0.35%

EGRX Stock Price

View Fullscreen

EGRX RSI Chart

EGRX Valuation

Market Cap

76.0M

Price/Earnings (Trailing)

5.78

Price/Sales (Trailing)

0.27

EV/EBITDA

3.23

Price/Free Cashflow

-7.36

EGRX Price/Sales (Trailing)

EGRX Profitability

Free Cashflow Yield

-13.59%

EGRX Fundamentals

EGRX Revenue

EGRX Earnings

Breaking Down EGRX Revenue

Last 7 days

-0.9%

Last 30 days

25.5%

Last 90 days

37.3%

Trailing 12 Months

-69.6%

How does EGRX drawdown profile look like?

EGRX Financial Health

EGRX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	267.0M	257.6M	0	0
2022	246.2M	272.2M	298.2M	316.6M
2021	183.0M	189.2M	179.1M	171.5M
2020	192.1M	177.4M	186.1M	187.8M
2019	216.5M	213.9M	203.7M	195.9M
2018	206.5M	215.7M	204.0M	213.3M
2017	236.7M	245.9M	271.1M	236.7M
2016	59.5M	94.4M	126.5M	189.5M
2015	50.5M	50.7M	53.6M	66.2M
2014	20.2M	20.9M	19.1M	19.2M
2013	6.3M	10.0M	13.7M	17.7M
2012	0	0	2.5M	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Eagle Pharmaceuticals Inc-DE

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

CEO	Mr. Scott L. Tarriff
WEBSITE	eagleus.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	134

Eagle Pharmaceuticals Inc-DE Frequently Asked Questions

What is the ticker symbol for Eagle Pharmaceuticals Inc-DE? What does EGRX stand for in stocks?

EGRX is the stock ticker symbol of Eagle Pharmaceuticals Inc-DE. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eagle Pharmaceuticals Inc-DE (EGRX)?

As of Thu Jul 25 2024, market cap of Eagle Pharmaceuticals Inc-DE is 75.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EGRX stock?

You can check EGRX's fair value in chart for subscribers.

Is Eagle Pharmaceuticals Inc-DE a good stock to buy?

The fair value guage provides a quick view whether EGRX is over valued or under valued. Whether Eagle Pharmaceuticals Inc-DE is cheap or expensive depends on the assumptions which impact Eagle Pharmaceuticals Inc-DE's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EGRX.

What is Eagle Pharmaceuticals Inc-DE's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, EGRX's PE ratio (Price to Earnings) is 5.78 and Price to Sales (PS) ratio is 0.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EGRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eagle Pharmaceuticals Inc-DE's stock?

In the past 10 years, Eagle Pharmaceuticals Inc-DE has provided -0.076 (multiply by 100 for percentage) rate of return.